Anacetrapib.
Merck & Co. is developing anacetrapib (MK 0859; MK-0859; MK0859), a selective cholesterol ester transfer protein (CETP) inhibitor, as a treatment for atherosclerosis, hypercholesterolemia, and mixed dyslipidemia. Add-on therapy with anacetrapib is currently being evaluated in a 76-week phase III trial in patients with coronary heart disease (CHD) or CHD risk-equivalent disease in the US, Germany, Spain, and Austria. This review discusses the development history and scientific profile of this new compound.
D050197:Atherosclerosis / Q000188:drug therapy; D053480:Cholesterol Ester Transfer Proteins / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology; D050171:Dyslipidemias / Q000188:drug therapy; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D023303:Oxazolidinones / Q000494:pharmacology* / Q000627:therapeutic use
D053480:Cholesterol Ester Transfer Proteins; D023303:Oxazolidinones; C530884:anacetrapib